BNET Industries
Amylin Pharmaceuticals Inc. (AMLN) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $780.9M
- Profit
- Dec 31 2007
- ($211.1M)
- Market Cap
- Sep 03 2008
- $3.0B
Latest News and Analysis
Five Presentations from the Recent Biotech Investment Conference
Mike Huckman submits: Medivation's Presentation: Standing Room Only A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer PFE, Medivation MDVN had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at yesterday's BioCentury/Thomson Reuters biotech investment conference...
Five Biopharma Companies Drop on Negative Drug News
Mike Huckman submits: Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals AMLN and Cell Genesys CEGE, much lower. After the closing bell Tuesday, Bristol-Myers Squibb BMY and Pfizer PFE announced a bloodclot drug...
Wednesday Options Update: LEH, AMLN, XLE, NTAP, CLNE, HOS, DLTR, TEL, ESI
Rebecca Engmann Darst contributed to this report. Lehman Brothers LEH – A more positive tone for Lehman’s today has shares knocking on the door of the $15.00 mark having rallied by 6.3% so far Wednesday. Options volume puts Lehman’s on our scanner of most actively traded equity options today....
Amylin, Lilly: Another Case of a Panic Driven Sell-Off
A. Reza Saadat submits: On Tuesday August 26, Amylin AMLN and its partner Eli Lilly LLY announced that four patients had died while on diabetes treatment Byetta.Both Amylin (down 12%) and Lilly (down 1%) sold off in after hours following repeated headlines saying Byetta was responsible for the...
Drug Safety Updates For Elan, Biogen, Amylin, and Lilly
Mike Huckman submits: After the closing bell Monday, Eli Lilly LLY and Amylin Pharmaceuticals AMLN announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Last week, the Food and Drug Administration revealed that six patients on the drug had to...
Amylin Shares Gain Ground on Outlook for Byetta
Trader Mark submits: I've been stating for a while now that this market has changed character - even as the bear market hit us in the winter we were still able to find pockets of strength where buying breakouts were rewarded. However, at this time, instead of buying breakouts, the...
Wednesday Options Update: MER, BAC, FNM, AMGN, AMLN, LLY, MEA, GE
Rebecca Engmann Darst contributed to this report. Merrill Lynch MER – Financial shares started the day on shaky footing following Goldman Sachs’ downgrade of profit estimates and share price targets for a slew of banks and brokerages, leaving traders understandably wary of what’s waiting behind the proverbial Door #3....
Why I'm Buying Amylin Now
Trader Mark submits: I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals AMLN. This is one of the few biotechs I know pretty well, and have followed for quite a while - mostly...
AstraZeneca Gives FluMist Spray a Shot in the Arm
Mike Huckman submits: Ads for flu vaccines have traditionally been confined to public service announcements PSAs, health and media alerts. So, that's why I was surprised to see this colorful full-page ad in The New York Times last weekend for FluMist from AstraZeneca AZN/MedImmune. by Mike Huckman
5 Potential Buyout Targets in Biotech - Barron's
Bristol-Myers Squibb BMY made a $4.5B bid for the shares of ImClone IMCL it doesn't already own. Roche Holdings (RHHBY.PK) made a $44B offer for the shares of Genetech DNA it doesn't own. Both targets want the bid prices raised. Barron's Lawrence Strauss says these are just the two latest...
My Model Biotech Picks: What's Hot and What's Not
A. Reza Saadat submits: Analyzing the performance of my previous picks is by far my favorite part of writing this blog. It has on many occasions allowed be to learn from my mistakes.I have moved the numbers to Google docs so that they are easier to read. Here is...
Icahn Racks Up Gains in ImClone, Motorola, and Amylin
Lon Juricic submits: Activist investor Carl Icahn had a nice day yesterday. Here's why:Bristol-Myers BMY sent Mr. Icahn a letter presenting a $60 per share offer for ImClone Systems IMCL. Icahn is the Chairman of ImClone, and owns 11,669,544 shares of the biotech company. With shares of ImClone...
Amylin Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Amylin Pharmaceuticals, Inc. AMLN Q2 FY08 Earnings Call
Amylin Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Amylin Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Amylin Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Amylin Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Amylin Pharmaceuticals Q3 2007 Earnings Call Transcript
Amylin Pharmaceuticals Q3 2007 Earnings Call Transcript
Amylin Pharmaceuticals Q2 2007 Earnings Call Transcript
Amylin Pharmaceuticals Q2 2007 Earnings Call Transcript
Additional Resources
4 More Deaths Reported Among Byetta Patients
The makers of the type 2 diabetes drug Byetta reported Tuesday the deaths of four more people who'd been taking the medication. The announcement by Eli Lilly and Amylin Pharmaceuticals Inc. came a week after the U.S. Food and Drug Administration said that two Byetta users had died of acute...
Stocks on the move: Borders, Cell Genesys, Fannie Mae, Talbots
By Lynn Thomasson Bloomberg News The following companies are having unusual price changes in U.S. markets this morning. Airlines retreated after Citigroup Inc. said "significant risks remain" for U.S. carriers and oil jumped more than $2 a barrel, its third day...
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
SAN DIEGO and INDIANAPOLIS, Aug. 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company in a conference call today provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration FDA update to a prior alert for BYETTAR exenatide injection referencing...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Incorporated: 1987
- CEO: Mr. Daniel M. Bradbury
Amylin Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases. Co. sells BYETTA® (exenatide) injection and SYMLIN®(pramlintide acetate) injection for the treatment of patients with diabetes. Co. also has development programs in the therapeutic areas of diabetes and obesity, including exenatide once weekly for diabetes; pramlintide acetate and PYY 3-36 for the treatment of obesity; and Leptin for the treatment of obesity and lipodystrophy. Co. serves healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payors.
Key Competitors
Amylin Pharmaceuticals Inc. Company Info
Board of Directors
Mr. Joseph C. Cook Jr.
Chairman
Dr. Jay S. Skyler M.D.
Mr. Joseph P. Sullivan
Mr. James N. Wilson
Mr. Daniel M. Bradbury
Mr. Adrian Adams
Mr. Steven R. Altman
Ms. Teresa Beck
Ms. Karin Eastham
Dr. James R. Gavin III, M.D
Ms. Ginger L. Graham
Mr. Howard E. Greene Jr.
Contact Information
9373 Towne Centre Drive
San Diego, CA
858 552-2200
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
